16:52 , Jun 8, 2018 |  BC Week In Review  |  Clinical News

Frontier's HIV drug approved in China

Frontier Biotechnologies Co. Ltd. (Nanjing, China) said China’s State Drug Administration approved once-weekly albuvirtide to treat treatment-experienced patients with HIV infection in combination with other antiretrovirals. The company said it is the first approved HIV...
21:25 , Jun 5, 2018 |  BC Extra  |  Company News

Frontier's HIV drug approved in China

Frontier Biotechnologies Co. Ltd. (Nanjing, China) said China’s State Drug Administration approved once-weekly albuvirtide to treat treatment-experienced patients with HIV infection in combination with other antiretrovirals. The company said it is the first approved HIV...
00:57 , Feb 14, 2018 |  BC Innovations  |  Distillery Techniques

Assays and screens

TECHNOLOGY: Cellular assays; high throughput screening A high throughput yeast-based method of antibody screening could help identify therapeutic antibodies in human blood. The method involves three steps: engineering a yeast strain with cell-surface expression of a...
23:06 , Jan 31, 2017 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: HIV / AIDS Patient sample and cell culture studies identified a chimeric, broadly neutralizing antibody (bNAb) against HIV gp41 that could help treat HIV infection. Thirty-five chimeric bNAbs were engineered by swapping the heavy and...
23:51 , Jan 6, 2017 |  BC Extra  |  Financial News

Frontier raises RMB300M in series C

Frontier Biotechnologies Co. Ltd. (Nanjing, China) said it raised RMB300 million ($43.2 million) in a series C round led by Huaxin Century. Shenzhen Capital, Efung Capital and undisclosed other investors also participated. Frontier said it...
07:00 , Jul 11, 2016 |  BC Week In Review  |  Clinical News

Albuvirtide: Interim Phase III data

Interim data from 96 evaluable HIV-infected patients who failed first-line antiretroviral therapy (ART) in the modified intent-to-treat (mITT) population of the open-label, Chinese Phase III TALENT trial showed that once-weekly 320 mg IV albuvirtide plus...
08:00 , Dec 3, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: Co-crystal structures of HIV env trimer bound to a broadly neutralizing antibody (bNAb) against HIV-1

Drug platformsHIV envHIV gp41Inovio Pharmaceuticals Inc.Pennvax-GPCalifornia Institute of Technology...
07:00 , Aug 10, 2015 |  BC Week In Review  |  Clinical News

VAC-3S: Additional Phase I data

The double-blind, French Phase I IVVAC-3S/P1 trial in about 33 patients with HIV-1 infection receiving antiretroviral therapy (ART) with undetectable viral loads showed that VAC-3S met the primary safety endpoint. VAC-3S was well tolerated and...
07:00 , Jul 23, 2015 |  BC Innovations  |  Product R&D

Sealing the envelope

Research from two academic groups could bring HIV vaccines a step closer to the finish line by identifying new ways to stabilize trimers of the HIV envelope protein. The greater stability raises the chances that...
07:00 , Jul 16, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: HIV gp140; HIV gp120; HIV gp41

Infectious disease INDICATION: HIV / AIDS Animal studies suggest stabilized HIV gp140 trimers could be used to develop vaccines that elicit broadly neutralizing antibodies (bNAbs). Stabilized HIV gp140 trimers were engineered with a disulfide bond to link...